{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:33:41Z","timestamp":1788993221676,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several studies have explored the impact of immune checkpoint inhibitor (ICI)\u2013induced immune-related thyroid dysfunction on the prognosis of patients with lung cancer. However, inconsistencies remain among the results of different studies. Therefore, we conducted a meta-analysis to evaluate the impact of immune-related thyroid dysfunction on the prognosis of lung cancer, aiming to provide evidence-based support for clinical treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, the China National Knowledge Infrastructure (CNKI), and the Cochrane Library to identify studies on the association between immune-related thyroid dysfunction and the prognosis of patients with lung cancer. The search period spanned from the establishment of each database to November 2025. Two researchers independently performed literature screening, data extraction, and assessment of the risk of bias in the included studies. A meta-analysis was performed using RevMan 5.3 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 14 studies involving 2,252 patients with lung cancer were included. The meta-analysis showed that ICI-induced immune-related thyroid dysfunction improved the overall survival (OS) (HR = 0.47, 95% confidence interval, CI [0.39, 0.56],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001) and progression-free survival (PFS) (HR = 0.44, 95% CI [0.38, 0.52],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001) in patients with lung cancer. Subgroup analysis revealed that in both Asian and non-Asian populations, ICI-induced immune-related thyroid dysfunction was associated with improved OS (Asian: HR = 0.53, 95% CI [0.43, 0.66],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001; non-Asian: HR = 0.32, 95% CI [0.22, 0.45],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001) and PFS (Asian: HR = 0.45, 95% CI [0.38, 0.55],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001; non-Asian: HR = 0.42, 95% CI [0.30, 0.58],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001) in patients with lung cancer. Additionally, both ICI-induced hypothyroidism and hyperthyroidism improved OS in patients with lung cancer (hypothyroidism: HR = 0.47, 95% CI [0.33, 0.68],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001; hyperthyroidism: HR = 0.28, 95% CI [0.15, 0.53],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with lung cancer receiving immunotherapy, the development of thyroid dysfunction (a treatment-related adverse event) may indicate a more robust immune response to the therapy, which is associated with improved treatment outcomes. This finding provides evidence-based support for predicting the prognosis of patients with lung cancer treated with ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251267541.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1743245","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:27:47Z","timestamp":1768886867000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune checkpoint inhibitors-induced thyroid dysfunction improves the prognosis of patients with lung cancer: a meta-analysis and systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nan\u2019an District People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shenzhen Shenshan People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqiao","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Army Medical Center of PLA","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nan\u2019an District People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162882","article-title":"The genetic analysis and clinical therapy in lung cancer: current advances and future directions","volume":"16","author":"Rina","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.intonc.2024.11.003","article-title":"Artificial intelligence in clinical trials of lung cancer: current and future prospects","volume":"1","author":"Zhang","year":"2025","journal-title":"Intell Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2016-0373","article-title":"Mitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now","volume":"11","author":"Nam","year":"2017","journal-title":"biomark Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13061174","article-title":"A cad system for lung cancer detection using hybrid deep learning techniques","volume":"13","author":"Alsheikhy","year":"2023","journal-title":"Diagnost (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/hm9.0000000000000158","article-title":"Electroacupuncture combined with cisplatin induces an effective anti-tumor immune response by protecting chemotherapy-impaired bone marrow hematopoiesis in non\u2013small cell lung cancer mice","volume":"5","author":"Wang","year":"2025","journal-title":"Acupunct Herbal Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080248","article-title":"Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells","volume":"10","author":"Testa","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/138920210793175903","article-title":"Lung cancer: are we up to the challenge","volume":"11","author":"Esposito","year":"2010","journal-title":"Curr Genomics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.intonc.2025.05.001","article-title":"A narrative review of the prediction of immunotherapy efficacy for treating nsclc: an artificial intelligence perspective","volume":"1","author":"Wu","year":"2025","journal-title":"Intell Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.13699\/j.cnki.1001-6821.2023.17.003","article-title":"Clinical efficacy of recombinant human endostatin combined with albumin paclitaxel in the treatment of advanced lung cancer patients","volume":"39","author":"Bao","year":"2023","journal-title":"Chin J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1845","article-title":"Epidemiology of adenosquamous carcinomas","volume":"15","author":"Benesch","year":"2024","journal-title":"World J Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.859938","article-title":"Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China","volume":"12","author":"Miao","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.699060","article-title":"Application of immunotherapy in hepatocellular carcinoma","volume":"11","author":"Miao","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1138493","article-title":"Immunotherapies for advanced hepatocellular carcinoma","volume":"14","author":"Sun","year":"2023","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020251","article-title":"The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01605","article-title":"Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/biology10060561","article-title":"Rheumatic immune-related adverse events-a consequence of immune checkpoint inhibitor therapy","volume":"10","author":"Bobirc\u0103","year":"2021","journal-title":"Biol (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.17925\/ee.2021.17.1.21","article-title":"Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies","volume":"17","author":"George","year":"2021","journal-title":"touchREV Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1169173","article-title":"Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study","volume":"14","author":"Lee","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: A retrospective study","volume":"81","author":"Wu","year":"2023","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21873\/cdp.10076","article-title":"Immune-related thyroid dysfunction (Irtd) in non-small cell lung cancer (Nsclc) correlates with response and survival","volume":"2","author":"Chilelli","year":"2022","journal-title":"Cancer Diagnosis Prognosis"},{"key":"B25","volume-title":"Clinical Features and Prognosis of Thyroid Dysfunction Induced by Pd-1 Inhibitor in Advanced Non-Small Cell Lung Cancer [Master]","author":"Feng","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495460","article-title":"Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: A real-world retrospective study","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Presse Medicale (Paris France: 1983)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402x.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to pd-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630136","article-title":"Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: A retrospective study","volume":"11","author":"Morimoto","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/HM9.0000000000000029","article-title":"Acupuncture and moxibustion treating lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and network meta-analysis","volume":"2","author":"Chen","year":"2022","journal-title":"Acupunct Herbal Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Res ed)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/HM9.0000000000000172","article-title":"Effectiveness of acupuncture in managing aromatase inhibitor-related arthralgia in breast cancer: A systematic review and meta-analysis","volume":"5","author":"Zhu","year":"2025","journal-title":"Acupunct Herbal Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02268-0","article-title":"Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study","volume":"47","author":"Albertelli","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0921","article-title":"Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with pd-1 blockade in non-small cell lung cancer","volume":"27","author":"Luo","year":"2021","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01871-7","article-title":"Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes","volume":"64","author":"Peir\u00f3","year":"2019","journal-title":"Endocrine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02802-6","article-title":"Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study","volume":"70","author":"Thuillier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","article-title":"Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors","volume":"70","author":"Lima Ferreira","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631949","article-title":"Immune-related adverse events predict the efficacy of immune checkpoint inhibitors in lung cancer patients: A meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector Cd8(+) T cells driven by Il-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Trans Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","article-title":"Cd4(+) T cells are essential for the development of destructive thyroiditis induced by anti-pd-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Trans Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: A case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/105072502753451896","article-title":"Polymorphism of the ctla-4 gene is associated with autoimmune hypothyroidism in the United Kingdom","volume":"12","author":"Nithiyananthan","year":"2002","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of ctla-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocr J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/1750743x.2024.2353539","article-title":"Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event","volume":"16","author":"Sasaki","year":"2024","journal-title":"Immunotherapy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13429","article-title":"Thyroid Dysfunction During Pd-1 Inhibitor Treatment in Patients with Cancer: Incidence and Association with Progression-Free Survival","volume":"24","author":"Wu","year":"2022","journal-title":"Oncology letters"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid Function Abnormality Induced by Pd-1 Inhibitors Have a Positive Impact on Survival in Patients with Non-Small Cell Lung Cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"International immunopharmacology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, Features, and Prognosis of Immune-Related Adverse Events Involving the Thyroid Gland Induced by Nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PloS one"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1743245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:27:48Z","timestamp":1768886868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1743245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":55,"alternative-id":["10.3389\/fendo.2025.1743245"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1743245","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1743245"}}